Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial

Diabetes, Obesity and Metabolism

Volumn 21, Issue 11, 2019, Pages 2440-2449

  Baker, Claire ^a   Wason, Suman ^b   Banks, Phillip ^b   Sawhney, Sangeeta ^b   Chang, Anna ^c   Danne, Thomas ^d   Gesty Palmer, Diane ^b   Kushner, Jake A ^e   McGuire, Darren K ^f   Mikell, Frank ^g   O'Neill, Mark ^b   Peters, Anne L ^h   Strumph, Paul ^b  

^a Diabetes and Endocrine Associates   (United States)

^b LEXICON PHARMACEUTICALS INC   (United States)

^c John Muir Physician Network Clinical Research Center   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e McNair Medical Institute   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g Hospital Sisters Health System Medical Group   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

glycaemic control; insulin therapy; phase 2 study; randomized trial; SGLT2 inhibitor; type 1 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; GLYCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSURIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEAST SQUARE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; URINARY EXCRETION; URINARY TRACT INFECTION; ADMINISTRATION AND DOSAGE; ADVERSE EVENT; CLINICAL TRIAL; KETOACIDOSIS; METABOLISM; MIDDLE AGED;

ADULT; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLYCATED HEMOGLOBIN A; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; KETOSIS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85070069138     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13825     Document Type: Article

References (35)

1. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38(6):971-978.
2. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32(8):1036-1050.
3. Weiss R, Garg SK, Bode BW, et al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE In-Home Study. Diabetes Technol Ther. 2015;17(8):542-547.
4. Lu CL, Shen HN, Hu SC, Wang JD, Li CY. A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes. Diabetes Care. 2016;39(9):1571-1578.
5. Purnell JQ, Braffett BH, Zinman B, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Care. 2017;40(12):1756-1762.
6. Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597-609.
7. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19(1):19-28.
8. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28(10):1176-1181.
9. Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702-1710.
10. Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract. 2016;22(2):220-230.
11. Lyons SK, Hermann JM, Miller KM, et al. Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D exchange registries. Diabetes Care. 2017;40(10):e139-e140.
12. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337-2348.
13. Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study. Diabetes Care. 2018;41(9):1970-1980.
14. Danne T, Cariou B, Banks P, et al. HbA1c and hypoglycemia reduction at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981-1990.
15. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864-876.
16. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258-2265.
17. Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938-1946.
18. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res. 2015;12(2):101-110.
19. Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol. 2015;308(11):G946-G954.
20. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther. 2013;35(8):1162-1173.e1168.
21. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181-1188.
22. Danne T, Cariou B, Buse JB, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program. Diabetes Care. 2019;42(5):919-930.
23. Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.
24. Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28(2):301-306.
25. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17(10):928-935.
26. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412-419.
27. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38(3):431-438.
28. Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin decreases postprandial glucose and insulin by delaying intestinal glucose absorption. Endo2019; March 23–26, 2019, 2019; New Orleans, LA.
29. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
30. Pieber TR, Famula S, Eilbracht J, et al. Empagliflozin reduces HbA1c with lower insulin doses in patients with type 1 diabetes: a 4-week placebo-controlled trial (EASE-1). European Association for the Study of Diabetes Annual Meeting; 2015; Stockholm, Sweden.
31. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab. 2017;19(6):814-821.
32. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39(4):532-538.
33. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693.
34. Garg SK, Strumph P. Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med. 2018;378(10):967-968.
35. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S173-s181.